Working… Menu
Trial record 1 of 2 for:    sarilumab | gca
Previous Study | Return to List | Next Study

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03600805
Recruitment Status : Terminated (Protracted recruitment timeline exacerbated by COVID-19 pandemic)
First Posted : July 26, 2018
Last Update Posted : December 28, 2020
Regeneron Pharmaceuticals
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : November 24, 2020
Actual Study Completion Date : November 24, 2020